BioCentury | Mar 23, 2020
Product Development

March 23 Quick Takes: Venclexta combo hits in AML; plus Jardiance rebuffed, Zolgensma approved in Japan and Zealand-Boehringer

Venclexta combo shows survival benefit in AML  Partners Roche (SIX:ROG; OTCQX:RHHBY) and AbbVie Inc. (NYSE:ABBV) said Venclexta venetoclax plus azacitidine significantly improved overall survival and composite complete remission rate among acute myelogenous leukemia (AML) patients...
BC Week In Review | Sep 20, 2019
Company News

China exempts 12 cancer drugs from tariffs

China is exempting 12 cancer drugs from tariffs imposed on U.S. goods, the first time China has offered tariff relief since the trade war began last year. The 12 drugs include Iressa gefitinib and Tomudex...
BC Extra | Jun 7, 2019
Clinical News

June 7 Clinical Quick Takes: Takeda discontinues Ninlaro for amyloidosis; plus La Jolla, Innovent and Atara

Takeda discontinues amyloidosis trial  Takeda Pharmaceutical Co. Ltd. (Tokyo:4502; NYSE:TAK) discontinued the Phase III TOURMALINE-AL1 trial to treat relapsed or refractory systemic amyloid light-chain (AL) amyloidosis after Ninlaro ixazomib plus dexamethasone missed the first of...
BioCentury | Apr 19, 2019
Product Development

Companies poised to take Chinese checkpoints global

At least three companies are well positioned to answer FDA Oncology chief Richard Pazdur’s call to bring Chinese PD-1/PD-L1 inhibitors to the U.S. to compete on price. Two Chinese drugmakers and one U.S. company globally...
BC Week In Review | Nov 30, 2018
Clinical News

FDA approves two drugs for first-line AML

FDA approved on Nov. 28 two drugs for first-line treatment of acute myelogenous leukemia, setting off a race in a setting that's been void of new approvals for patients who do not harbor an FMS-like...
BC Extra | Nov 21, 2018
Company News

FDA approves two drugs for first-line AML

FDA approved on Wednesday two drugs for first-line treatment of acute myelogenous leukemia, setting off a race in a setting that's been void of new approvals for patients who do not harbor an FMS-like tyrosine...
BC Week In Review | Aug 3, 2018
Clinical News

Otsuka's guadecitabine misses in Phase III for first-line AML

Otsuka Pharmaceutical Co. Ltd. (Tokyo, Japan) and its Astex Pharmaceuticals Inc. subsidiary said first-line treatment with guadecitabine (formerly SGI-110) missed the co-primary endpoints in the Phase III ASTRAL-1 trial to treat previously untreated acute myelogenous...
BC Extra | Jul 31, 2018
Clinical News

Otsuka's guadecitabine misses in Phase III for first-line AML

Otsuka Pharmaceutical Co. Ltd. (Tokyo, Japan) and its Astex Pharmaceuticals Inc. subsidiary said first-line treatment with guadecitabine (formerly SGI-110) missed the co-primary endpoints in the Phase III ASTRAL-1 trial to treat previously untreated acute myelogenous...
BC Week In Review | Apr 13, 2018
Company News

Novo Nordisk licenses sickle cell candidate from EpiDestiny

EpiDestiny Inc. (Solon, Ohio) granted Novo Nordisk A/S (CSE:NOVOB; NYSE:NVO) exclusive, worldwide rights to EPI01 to treat sickle cell disease (SCD) and beta-thalassemia. EpiDestiny is eligible for more than $400 million, comprising a $12 million...
BC Extra | Apr 5, 2018
Company News

Novo in deal for EpiDestiny's hematology candidate

EpiDestiny Inc. (Solon, Ohio) granted Novo Nordisk A/S (CSE:NOVOB; NYSE:NVO) exclusive, worldwide rights to EPI01 to treat sickle cell disease (SCD) and beta-thalassemia. EpiDestiny is eligible for more than $400 million, comprising a $12 million...
Items per page:
1 - 10 of 294